HUT71550A - Pharmaceutical agents containing quinuclidine, piperidine or azanorbornane derivatives for treatment of emesis - Google Patents

Pharmaceutical agents containing quinuclidine, piperidine or azanorbornane derivatives for treatment of emesis

Info

Publication number
HUT71550A
HUT71550A HU9401676A HU9401676A HUT71550A HU T71550 A HUT71550 A HU T71550A HU 9401676 A HU9401676 A HU 9401676A HU 9401676 A HU9401676 A HU 9401676A HU T71550 A HUT71550 A HU T71550A
Authority
HU
Hungary
Prior art keywords
piperidine
emesis
treatment
pharmaceutical agents
derivatives
Prior art date
Application number
HU9401676A
Other languages
Hungarian (hu)
Other versions
HU222243B1 (en
HU9401676D0 (en
Inventor
Manoj C Desai
John W Watson
John A Lowe Iii
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HU9401676D0 publication Critical patent/HU9401676D0/en
Publication of HUT71550A publication Critical patent/HUT71550A/en
Publication of HU222243B1 publication Critical patent/HU222243B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

The present invention relates to compounds useful for treating or preventing emesis in mammals, including humans, using certain quinuclidine derivatives, piperidine derivatives, azanorbornane derivatives and related compounds.
HU9401676A 1993-06-04 1994-06-03 Process for the preparation of pharmaceutical compositions containing piperidine or azabicyclooctane derivatives for treatment of emesis HU222243B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/072,629 US5393762A (en) 1993-06-04 1993-06-04 Pharmaceutical agents for treatment of emesis

Publications (3)

Publication Number Publication Date
HU9401676D0 HU9401676D0 (en) 1994-09-28
HUT71550A true HUT71550A (en) 1995-12-28
HU222243B1 HU222243B1 (en) 2003-05-28

Family

ID=22108825

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9401676A HU222243B1 (en) 1993-06-04 1994-06-03 Process for the preparation of pharmaceutical compositions containing piperidine or azabicyclooctane derivatives for treatment of emesis

Country Status (19)

Country Link
US (1) US5393762A (en)
EP (1) EP0627221B1 (en)
JP (1) JP2671972B2 (en)
KR (1) KR100190729B1 (en)
CN (1) CN1100535C (en)
AT (1) ATE209490T1 (en)
AU (1) AU666077B2 (en)
CA (1) CA2124990C (en)
DE (1) DE69429208T2 (en)
DK (1) DK0627221T3 (en)
ES (1) ES2164088T3 (en)
HU (1) HU222243B1 (en)
IL (1) IL109802A (en)
MY (1) MY115310A (en)
NZ (1) NZ260674A (en)
PT (1) PT627221E (en)
RU (1) RU2135179C1 (en)
TW (1) TW318791B (en)
ZA (1) ZA943896B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0587723T3 (en) * 1991-05-31 1996-04-01 Pfizer quinuclidine derivatives
UA39168C2 (en) * 1991-06-20 2001-06-15 Пфайзер, Інк. Fluoroalkoxyphenyl derivatives of pyperidine or quinuclidine AS antagonists of P substance and pharmaceutical composition based thereon
EP0916346A3 (en) 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
DE69318854T2 (en) * 1993-03-04 1998-10-08 Pfizer SPIROAZACYCLIC DERIVATIVES AS SUBSTANCE P ANTAGONISTS
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
WO1996030367A1 (en) * 1995-03-27 1996-10-03 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW458774B (en) * 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
GB9708484D0 (en) 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
CA2291734A1 (en) * 1997-06-27 1999-01-07 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
EP1145714A4 (en) * 1998-11-27 2004-12-15 Takeda Chemical Industries Ltd Drugs
NZ501211A (en) * 1999-01-29 2001-10-26 Pfizer Prod Inc Pharmaceutical composition comprising macrolide antibiotic like erythromycin and a Substance P antagonist, and method for treating cancer, bacterial and protozoal infection in non-humans
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
HUP0401154A2 (en) * 2001-07-20 2004-10-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
JP5021318B2 (en) * 2004-01-30 2012-09-05 ファイザー・プロダクツ・インク Antibacterial preservatives for achieving multi-dose formulations using β-cyclodextrin in liquid dosage forms
AU2005216706B2 (en) 2004-01-30 2007-11-29 Pfizer Products Inc. NK-1 receptor antagonists anesthesia recovery
SI1713801T1 (en) * 2004-02-02 2008-04-30 Pfizer Prod Inc Process for preparation of 1-(2s,3s)-2-benzhydr yl-n-(5-tert-butyl-2-methoxybenzyl)quinuclidin-3-amine
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation
US11040947B2 (en) 2017-03-22 2021-06-22 The Research Foundation For The State University Of New York Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
HUT62891A (en) * 1990-06-01 1993-06-28 Pfizer Process for producing 3-amino-2-arylquinuclidine compounds and pharmaceuticql composition comprising such compounds
CA2086434C (en) * 1990-07-23 1998-09-22 John A. Lowe, Iii Quinuclidine derivatives
HUT68667A (en) * 1990-09-28 1995-07-28 Pfizer Fused ring analogs of nitrogen containing nonaromatic heterocycles
AU652407B2 (en) * 1991-01-10 1994-08-25 Pfizer Inc. N-alkyl quinuclidinium salts as substance P antagonists
DE69200921T2 (en) * 1991-03-01 1995-05-04 Pfizer 1-AZABICYCLO [3.2.2] NONAN-3-AMINE DERIVATIVES.
BR9205807A (en) * 1991-03-26 1994-06-28 Pfizer Stereo-selective preparation of substituted piperidines
DE69232334T2 (en) * 1991-05-22 2002-11-14 Pfizer Inc., New York SUBSTITUTED 3-AMINOCHINUCLIDINE
DK0587723T3 (en) * 1991-05-31 1996-04-01 Pfizer quinuclidine derivatives
UA39168C2 (en) * 1991-06-20 2001-06-15 Пфайзер, Інк. Fluoroalkoxyphenyl derivatives of pyperidine or quinuclidine AS antagonists of P substance and pharmaceutical composition based thereon
TW202432B (en) * 1991-06-21 1993-03-21 Pfizer
EP0916346A3 (en) * 1991-09-20 2000-12-06 Glaxo Group Limited NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
BR9206500A (en) * 1991-09-26 1995-10-03 Pfizer Heterocycles containing condensed tricyclic nitrogen as antagonists of the P receptor substance
ATE161821T1 (en) * 1991-11-12 1998-01-15 Pfizer AZYCLIC ETHYLENEDIAMINE DERIVATIVES AS 'SUBSTANCE P RECEPTOR' ANTAGONISTS
JP2656702B2 (en) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 Peptide quinuclidine
CA2134964C (en) * 1992-05-18 1997-12-30 Manoj C. Desai Bridged aza-bicyclic derivatives as substance p antagonists
DE69328975T2 (en) * 1992-12-10 2000-11-09 Pfizer Inc., New York AMINOMETHYLENE SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALSO SUBSTANCE P ANTAGONISTS
DE69318854T2 (en) * 1993-03-04 1998-10-08 Pfizer SPIROAZACYCLIC DERIVATIVES AS SUBSTANCE P ANTAGONISTS
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
EP1105789A1 (en) * 1998-08-14 2001-06-13 ViA, Inc. Mobile robotic snake

Also Published As

Publication number Publication date
TW318791B (en) 1997-11-01
ZA943896B (en) 1995-12-04
HU222243B1 (en) 2003-05-28
CN1121806A (en) 1996-05-08
KR950000144A (en) 1995-01-03
IL109802A0 (en) 1994-08-26
JP2671972B2 (en) 1997-11-05
EP0627221A2 (en) 1994-12-07
EP0627221B1 (en) 2001-11-28
NZ260674A (en) 2000-07-28
US5393762A (en) 1995-02-28
DK0627221T3 (en) 2002-02-11
KR100190729B1 (en) 1999-06-01
DE69429208D1 (en) 2002-01-10
CA2124990C (en) 1999-04-20
JPH0753362A (en) 1995-02-28
HU9401676D0 (en) 1994-09-28
AU666077B2 (en) 1996-01-25
RU94020410A (en) 1996-05-10
MY115310A (en) 2003-05-31
ES2164088T3 (en) 2002-02-16
AU6452194A (en) 1994-12-15
CN1100535C (en) 2003-02-05
IL109802A (en) 2002-04-21
ATE209490T1 (en) 2001-12-15
PT627221E (en) 2002-04-29
EP0627221A3 (en) 1995-08-02
RU2135179C1 (en) 1999-08-27
DE69429208T2 (en) 2002-05-23

Similar Documents

Publication Publication Date Title
HUT71550A (en) Pharmaceutical agents containing quinuclidine, piperidine or azanorbornane derivatives for treatment of emesis
UA26213C2 (en) MEANS FOR PREVENTION AND TREATMENT OF OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITION AND THEIR BASES
ATE211384T1 (en) USE OF ADENOSINE ANTAGONISTS TO PREVENT AND TREAT PANCREATITIS AND ULCERAS
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
UA41355C2 (en) Agent for treating neuro-aids
GB9305718D0 (en) Medicaments
DK0701546T3 (en) Aromatic acetylcholinesterase inhibitors
ES2104358T3 (en) SILILED ACETYLCHOLINESTERASE INHIBITORS.
EP0328634A4 (en) Pharmaceutical compositions for the treatment of psoriasis
ES2093357T3 (en) ALOPECIA TREATMENT METHOD.
NO944339D0 (en) Melatonin derivatives for use in the treatment of sleep disorders
ZA932415B (en) Compounds for the treatment of neurodegenerative disorders
NO944340D0 (en) Melatonin derivatives for use in the treatment of desynchronization states
WO1996031208A3 (en) Use of substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders
CA2136801A1 (en) Pharmaceutical Agents for the Treatment of Disorders Caused by Helicobacter Pylori or Other Spiral Urease-Positive Gram-Negative Bacteria
MX9201825A (en) PHARMACEUTICAL COMPOSITION CONTAINING CALCITONIN.
EP0653208A3 (en) Pharmaceutical agents for treatment or prevention of sunburn.
MX9704035A (en) Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
IL98200A0 (en) Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide
DE59409129D1 (en) USE OF LITHIUM COMPOUNDS FOR TREATING AND PROPHYLAXIS OF ALZHEIMER'S MORBUS
GB9323550D0 (en) Composition for the treatment of hydrothyroidism

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20030325

MM4A Lapse of definitive patent protection due to non-payment of fees